Mostrar el registro sencillo del ítem

dc.contributor.authorLópez-Nieva, Pilar
dc.contributor.authorFernandez-Navarro, Pablo L 
dc.contributor.authorVaquero-Lorenzo, Concepción
dc.contributor.authorVilla-Morales, María
dc.contributor.authorGraña Castro, Osvaldo 
dc.contributor.authorCobos-Fernández, María Ángeles
dc.contributor.authorLópez-Lorenzo, José Luis
dc.contributor.authorLlamas, Pilar
dc.contributor.authorGonzález-Sanchez, Laura
dc.contributor.authorSastre, Isabel
dc.contributor.authorPollan-Santamaria, Marina 
dc.contributor.authorMalumbres Martinez, Marcos 
dc.contributor.authorSantos, Javier
dc.contributor.authorFernández-Piqueras, José
dc.date.accessioned2018-11-21T12:30:08Z
dc.date.available2018-11-21T12:30:08Z
dc.date.issued2018-04-16
dc.identifier.citationBMC Cancer. 2018 Apr 16;18(1):430.es_ES
dc.identifier.issn1471-2407es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6656
dc.description.abstractBackground: Precursor T-cell lymphoblastic lymphomas (T-LBL) are rare aggressive hematological malignancies that mainly develop in children. As in other cancers, the loss of cell cycle control plays a prominent role in the pathogenesis in these malignancies that is primarily attributed to loss of CDKN2A (encoding protein p16INK4A). However, the impact of the deregulation of other genes such as CDKN1C, E2F1, and TP53 remains to be clarified. Interestingly, experiments in mouse models have proven that conditional T-cell specific deletion of Cdkn1c gene may induce a differentiation block at the DN3 to DN4 transition, and that the loss of this gene in the absence of Tp53 led to aggressive thymic lymphomas. Results: In this manuscript, we demonstrated that the simultaneous deregulation of CDKN1C, E2F1, and TP53 genes by epigenetic mechanisms and/or the deregulation of specific microRNAs, together with additional impairing of TP53 function by the expression of dominant-negative isoforms are common features in primary human T-LBLs. Conclusions: Previous experimental work in mice revealed that T-cell specific deletion of Cdkn1c accelerates lymphomagenesis in the absence of Tp53. If, as expected, the consequences of the deregulation of the CDKN1C-E2F1-TP53 axis were the same as those experimentally demonstrated in mouse models, the disruption of this axis might be useful to predict tumor aggressiveness, and to provide the basis towards the development of potential therapeutic strategiesin human T-LBL.es_ES
dc.description.sponsorshipThe authors would like to thank Mario González-Sánchez and Javier González-Palacios ("Bioinformatics and Research Group in Genetic and Environmental Epidemiology", ISCIII) for their technical support. We thank all patients who were willing to donate their sample without their support the research work would not be possiblees_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCDKN1C-E2F1-TP53 deregulationes_ES
dc.subjectDeregulation of miRNAses_ES
dc.subjectPromoter hypermethylationes_ES
dc.subjectT-cell lymphoblastic lymphomaes_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshChild es_ES
dc.subject.meshCyclin-Dependent Kinase Inhibitor p57 es_ES
dc.subject.meshE2F1 Transcription Factor es_ES
dc.subject.meshEpigenesis, Genetic es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGene Expression Regulation, Neoplastic es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshMice es_ES
dc.subject.meshPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma es_ES
dc.subject.meshSequence Analysis, RNA es_ES
dc.subject.meshSignal Transduction es_ES
dc.subject.meshTumor Suppressor Protein p53 es_ES
dc.subject.meshYoung Adult es_ES
dc.titleRNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomases_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29661169es_ES
dc.format.volume18es_ES
dc.format.number1es_ES
dc.format.page430es_ES
dc.identifier.doi10.1186/s12885-018-4304-yes_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderComunidad de Madrid (España) 
dc.contributor.funderFundación Ramón Areces 
dc.contributor.funderBanco Santander 
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1471-2407es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12885-018-4304-y.es_ES
dc.identifier.journalBMC canceres_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología
dc.repisalud.institucionCNIOes_ES
dc.repisalud.institucionISCIII
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de División Celular y Cánceres_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SAF2015-70561-R


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional